AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] by Year
Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M) ($M)
AbbVie Eye Care Portfolio [folded into All Other in Q1 2026]: $2,109M in FY2025, down 5.9% from a year earlier.
Where the FY2025 figure comes from
“|| Eye Care | 954 | 1,155 | 2,109 | (10.2) | (2.0) | (5.9) | (1.2) | (5.5)”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,109 | -5.9% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 2,242 | -7.2% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 2,415 | -10.6% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 2,701 | -24.3% | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 3,567 | +63.3% | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 2,184 | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
Breakdown
What makes up eye Care Portfolio [folded into All Other in Q1 2026]
- Eye Care Portfolio [folded into All Other in Q1 2026] — U.S. net revenues ($M)954 · FY2025
- Eye Care Portfolio [folded into All Other in Q1 2026] — International net revenues ($M)1,155 · FY2025
- Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide reported growth YoY (%)-5.9% · FY2025
- Eye Care Portfolio [folded into All Other in Q1 2026] — Worldwide operational (constant-currency) growth YoY (%)-5.5% · FY2025
- Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M)493 · FY2025
- Lumigan/Ganfort (bimatoprost) — Worldwide net revenues ($M)410 · FY2025
- Alphagan/Combigan (brimonidine) — Worldwide net revenues ($M)197 · FY2025
- Restasis (cyclosporine ophthalmic emulsion) [legacy through FY24] — Worldwide net revenues ($M)224 · FY2024
- Other Eye Care — Worldwide net revenues ($M)1,009 · FY2025
Cite this data
StockData. (2026). AbbVie Eye Care Portfolio [folded into All Other in Q1 2026] ($M), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-eye-ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.